what is the outlook on abbott stock

Abbott’s outlook looks mixed but still constructive: the near-term pressure came from a lowered 2026 profit forecast after the Exact Sciences deal and softer flu-season sales, but analysts still see meaningful upside from here. Recent coverage also points to bullish hedge-fund positioning and an Overweight rating with a $115 price target from Piper Sandler.

What’s driving it

• Positive side: Abbott still has a strong base in medical devices, diagnostics, and nutrition, and some market coverage continues to frame it as a quality long-term compounder.
• Negative side: The latest guidance cut and acquisition-related costs have weighed on sentiment, and that is the main reason the stock has looked weaker in recent weeks.
• Street view: One recent market piece said analysts imply about 30.93% upside, while Piper Sandler reiterated an Overweight rating and $115 target.

How to read it

The story right now is less “broken business” and more “good company, near- term digestion.” Abbott’s longer-term fundamentals still matter, but investors are currently focused on whether management can stabilize earnings growth after the Exact Sciences impact and restore confidence with cleaner guidance.

Practical takeaway

• Bull case: recovery in earnings, continued revenue growth, and a rerating if execution stays solid.
• Bear case: slower-than-expected integration costs and lingering guidance pressure keep the stock range-bound.

• My read: Abbott looks more attractive for patient investors than for traders chasing a quick bounce.

The current setup suggests cautious optimism rather than a straight-line rally, with sentiment improving only if upcoming results show the guidance cut was temporary.